Format

Send to

Choose Destination
  • Filters activated: Field: Title Word. Clear all
Int J Nanomedicine. 2018 Apr 27;13:2561-2569. doi: 10.2147/IJN.S157746. eCollection 2018.

Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation.

Author information

1
Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou Shi, Jiangsu Sheng, People's Republic of China.
#
Contributed equally

Abstract

Purpose:

In this study, a novel arginine, glycine, aspartic acid peptide (RGD)-modified paclitaxel and curcumin co-loaded liposomes were developed to evaluate their antitumor activity in vitro and in vivo.

Materials and methods:

Co-loaded liposomes were prepared using the solvent evaporation method. The particles had spherical shapes under electron microscopy with sizes <130 nm.

Results:

By comparison with the free drug, RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes have sustained-release properties in vitro. In vivo, there was no significant difference in pharmacokinetic parameters between the RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes. A strong green fluorescence was observed in the cytoplasmic region after incubation of RGD-modified paclitaxel and curcumin co-loaded liposomes for 2 h. RGD-modified paclitaxel and curcumin co-loaded liposomes showed a superior antiproliferative effect on A549 cells with a possible mechanism that suppressed the multidrug resistance phenomenon and exhibited a clear synergistic effect.

Conclusion:

The results indicate that RGD-modified paclitaxel and curcumin co-loaded liposomes had a better antitumor effect in vivo than the non-modified LPs. These results indicate that RGD-modified co-loaded liposomes are a promising candidate for antitumor drug delivery.

KEYWORDS:

arginine; aspartic acid peptide; cell uptake; curcumin; cytotoxicity study; glycine; in vivo anti-tumor study; liposome; paclitaxel

PMID:
29731631
PMCID:
PMC5927341
DOI:
10.2147/IJN.S157746
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center